Cargando…

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial

CONTEXT: Control of multiple cardiovascular (CV) risk factors reduces CV events in individuals with type 2 diabetes. OBJECTIVE: To investigate this association in a contemporary clinical trial population, including how CV risk factor control affects the CV benefits of empagliflozin, a sodium-glucose...

Descripción completa

Detalles Bibliográficos
Autores principales: Inzucchi, Silvio E, Khunti, Kamlesh, Fitchett, David H, Wanner, Christoph, Mattheus, Michaela, George, Jyothis T, Ofstad, Anne Pernille, Zinman, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382052/
https://www.ncbi.nlm.nih.gov/pubmed/32485734
http://dx.doi.org/10.1210/clinem/dgaa321